Structure Therapeutics (NASDAQ:GPCR) Lowered to Strong Sell Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Structure Therapeutics to “strong sell” from “sell,” despite MarketBeat’s overall “moderate buy” consensus and average analyst price target of $110.91.
• Other analysts recently trimmed price targets, including HC Wainwright to $70 and Citizens JMP to $110, while Canaccord Genuity set a $111 target and maintained a positive outlook.
• Structure Therapeutics reported a quarterly loss of $0.49 per share, missing the $0.39 consensus estimate. The stock opened at $53.14, and institutional investors own approximately 91.78% of its shares.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) was downgraded by analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a research note issued to investors on Sunday.

A number of other equities analysts also recently commented on the stock. Canaccord Genuity Group set a $111.00 target price on shares of Structure Therapeutics in a research note on Friday. Citizens Jmp cut their price target on shares of Structure Therapeutics from $113.00 to $110.00 and set a "market outperform" rating for the company in a report on Friday. HC Wainwright lowered their price objective on Structure Therapeutics from $100.00 to $70.00 and set a "buy" rating for the company in a research report on Thursday, June 11th. Citigroup restated a "market outperform" rating on shares of Structure Therapeutics in a research report on Friday. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Structure Therapeutics in a research note on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $110.91.

Structure Therapeutics Stock Up 1.0%

Shares of NASDAQ GPCR opened at $53.14 on Friday. Structure Therapeutics has a 52 week low of $15.86 and a 52 week high of $94.90. The firm has a market cap of $3.78 billion, a P/E ratio of -53.14 and a beta of -1.43. The business's 50 day moving average price is $47.63 and its 200 day moving average price is $54.19.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). As a group, research analysts expect that Structure Therapeutics will post -1.64 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its stake in Structure Therapeutics by 18.5% in the second quarter. Geode Capital Management LLC now owns 54,181 shares of the company's stock valued at $1,124,000 after purchasing an additional 8,444 shares during the last quarter. Invesco Ltd. raised its stake in Structure Therapeutics by 7.6% during the 2nd quarter. Invesco Ltd. now owns 424,548 shares of the company's stock worth $8,805,000 after acquiring an additional 30,162 shares in the last quarter. Marshall Wace LLP lifted its position in Structure Therapeutics by 474.9% in the second quarter. Marshall Wace LLP now owns 176,060 shares of the company's stock valued at $3,651,000 after acquiring an additional 145,434 shares during the last quarter. Jump Financial LLC boosted its stake in Structure Therapeutics by 105.9% in the second quarter. Jump Financial LLC now owns 63,234 shares of the company's stock valued at $1,311,000 after acquiring an additional 32,524 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new position in shares of Structure Therapeutics during the second quarter worth about $3,480,000. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics NASDAQ: GPCR is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source